

Raynaud Disease

[View the current Raynaud Disease InDepth page on BioPortfolio.com](http://www.bioportfolio.com/indepth/Raynaud_Disease.html)

(http://www.bioportfolio.com/indepth/Raynaud_Disease.html)



Recent Publications on Raynaud Disease:

- [Systemic sclerosis/scleroderma: a treatable multisystem disease.](#)
*Systemic sclerosis (systemic scleroderma) is a chronic connective tissue...*19th November, 2008
Northwestern University, Feinberg School of Medicine, Chicago, Illinois- *Am Fam Physician*. 2008 Oct 15;78(8):961-8.
- [Cerebral vasospasm and primary Raynaud's phenomenon.](#)
*Systemic sclerosis (systemic scleroderma) is a chronic connective tissue...*19th November, 2008
- *Br J Anaesth*. 2008 Nov;101(5):743-4. ([DOI Direct Link](#))
- [Diagnostic workup for mixed connective tissue disease in childhood.](#)
*Raynaud's phenomenon, fatigue and pain (myalgia and arthralgia) are...*5th November, 2008
VU University Medical Center,- *Isr Med Assoc J*. 2008 Aug-Sep;10(8-9):650-2.
- [\[Role of videocapillaroscopy in early detection of transition from primary to secondary Raynaud's phenomenon in systemic sclerosis\]](#)
*Patients initially diagnosed as having primary Raynaud's phenomenon (PRP)...*4th November, 2008
U.O.C Clinica Reumatologica, Dipartimento di Medicina Interna, Universita- *Reumatismo*. 2008 Apr-Jun;60(2):102-7.
- [\[Nailfold capillaroscopy in the evaluation of Raynaud's phenomenon and undifferentiated connective tissue disease\]](#)
*BACKGROUND: Microvascular abnormalities involved in the pathogenic...*18th October, 2008
Instituto Portugues de Reumatologia, Lisboa Portugal.- *Acta Reumatol Port*. 2008 Apr-Jun;33(2):203-9.
- [Pulmonary artery hypertension as the presenting feature of systemic sclerosis sine scleroderma.](#)
*BACKGROUND: Microvascular abnormalities involved in the pathogenic...*15th October, 2008
- *Rheumatology (Oxford)*. 2008 Sep;47(9):1431-2. Epub 2008 Jun 28. ([DOI Direct Link](#))
- [Systemic sclerosis: an update for clinicians.](#)
*Recent advances in the management of systemic sclerosis highlight the...*1st October, 2008
Rheumatic Diseases Centre, Clinical Sciences Building, University of- *Br J Hosp Med (Lond)*. 2008 Aug;69(8):464-70.
- [Raynaud's phenomenon: pathogenesis and management.](#)
*Raynaud's phenomenon is a common clinical disorder for which patients...*1st October, 2008
Ronald O. Perelman Department of Dermatology, New York University Medical- *J Am Acad Dermatol*. 2008 Oct;59(4):633-53. Epub 2008 Jul 24. ([DOI Direct Link](#))
- [A potential role for imatinib and other small molecule tyrosine kinase inhibitors in the treatment of systemic and localized sclerosis.](#)
*Small molecule tyrosine kinase (TK) inhibitor, such as imatinib, is well...*1st October, 2008

Department of Dermatology at Boston University School of Medicine, Boston,- J Am Acad Dermatol. 2008 Oct;59(4):654-8. Epub 2008 Jun 20. ([DOI Direct Link](#))

- [Nodular scleroderma: a report of 2 cases.](#)
*Nodular scleroderma, also known as keloidal scleroderma, is a rare form of...*10th September, 2008
Division of Dermatopathology, Department of Dermatology, Hospital of the- Am J Dermatopathol. 2008 Aug;30(4):385-8. ([DOI Direct Link](#))
- [\[Definition and terminology of Raynaud's syndrome\]](#)
*Physicians have for a long time used different definitions, terminology...*20th August, 2008
- Dtsch Med Wochenschr. 2008 Aug;133(34-35):1742-4. ([DOI Direct Link](#))
- [Prognostic model based on nailfold capillaroscopy for identifying Raynaud's phenomenon patients at high risk for the development of a scleroderma spectrum disorder: PRINCE \(prognostic index for nailfold capillaroscopic examination\).](#)
*OBJECTIVE: To construct a prognostic index based on nailfold...*9th August, 2008
Department of Rheumatology, Instituto Gaetano Pini, University of Milan,- Arthritis Rheum. 2008 Jul;58(7):2174-82. ([DOI Direct Link](#))
- [Cardiovascular risk and prostanoids in systemic sclerosis.](#)
*OBJECTIVE: Systemic sclerosis (SSc) is characterized by Raynaud's...*29th July, 2008
Chair and Rheumatology Unit, University of Modena e Reggio Emilia, Medical- Clin Exp Rheumatol. 2008 Mar-Apr;26(2):333-6.
- [Improvement in both raynaud disease and hyperhidrosis in response to botulinum toxin type A treatment.](#)
*BACKGROUND: A patient with concurrent Raynaud disease presented for...*17th July, 2008
Division of Dermatology, University of Alberta, Edmonton, AB- J Cutan Med Surg. 2008 Jul-Aug;12(4):189-93.
- [\[Systemic sclerosis\]](#)
*Systemic sclerosis (SSc) is a severe fibrotic multiorgan connective tissue...*10th July, 2008
Rheumaklinik, Universitatsspital Zurich, Zurich, Schweiz.- Med Monatsschr Pharm. 2008 May;31(5):162-70; quiz 171-2.

BioNews Results for Raynaud Disease

- [GARDASIL\(R\), Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males](#)
Genetic Engineering News: Nov 13 2008 3:01PM Matching: raynaud disease

Raynaud Disease Clinical Trials:



- [Safety, Tolerability and Pharmacodynamic Profile of Oral 2101 Once Daily for up to 14 Days in Secondary Raynaud's Disease](#)
Secondary Raynaud's Disease



Raynaud Disease Patents:

- 7341995- [Use of SARP-1 for the treatment and/or prevention of scleroderma](#)
- 7365170- [Adiponectin and uses thereof](#)
- 7368270- [Human phospholipases](#)
- 7368527- [HADDE71 polypeptides](#)
- 7368531- [Human secreted proteins](#)
- 7371388- [Treatment of Sjogren's syndrome by administration of TR18 polypeptides](#)
- 7371772- [Bicyclic compound, production and use thereof](#)
- 7371822- [Human G-protein coupled receptor variant of HM74, HGPRBMY74](#)
- 7381699- [Reagents and methods for smooth muscle therapies](#)
- 7381800- [Antibodies to HBIMF63 polypeptide](#)
- 7384655- [Preparation of compositions to alleviate inflammation and oxidative stress in a mammal](#)
- 7365093- [Endothelin antagonists](#)
- 7365067- [Indanol derivative](#)
- 7361341- [Methods of treating cancer using antibodies that immunospecifically bind to trail receptors](#)
- 7344882- [Polynucleotides encoding variants of the TRP channel family member, LTRPC3](#)
- 7345148- [Human G-protein coupled receptor, HGPRBMY29sv1 polypeptides](#)
- 7348003- [Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors](#)
- 7348149- [Methods of diagnosing Parkinson's disease by measuring expression level of RNA encoding human protein HLLRCR-1](#)
- 7348335- [Compositions useful as inhibitors of JAK and other protein kinases](#)
- 7349743- [System, method, and resilient neurological stimulation lead for stimulation of a person's nerve tissue](#)
- 7351566- [27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552, and 65577 molecules and uses therefor](#)
- 7357927- [Death domain containing receptors](#)
- 7358074- [Human phosphatase RET31, and variants thereof](#)
- 7359748- [Apparatus for total immersion photography](#)
- 7384962- [Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them](#)
- 7384975- [Substituted furochromenes, preparation thereof and their antiinflammatory action](#)
- 7429646- [Antibodies to human tumor necrosis factor receptor-like 2](#)
- 7435547- [Therapeutic agent for fibromyalgia](#)
- 7435808- [Polynucleotides encoding novel adiponectin receptor variant, AdipoR2v2](#)
- 7435824- [Prodrugs of potassium channel inhibitors](#)
- 7442715- [Thiazole derivatives](#)
- 7442795- [Triazole compounds useful in therapy](#)
- 7446176- [12 human secreted proteins](#)
- 7449462- [Triazole derivatives which inhibit vasopressin antagonistic activity](#)
- 7452538- [Death domain containing receptor 4 antibodies and methods](#)
- 7456170- [Triazolobenzodiazepines and their use as vasopressin antagonists](#)
- 7429569- [Compositions and methods for the regulation of homocysteine levels within the body](#)
- 7425700- [Systems and methods for discovery and analysis of markers](#)
- 7425622- [Antibodies against C3a receptor](#)
- 7390637- [Keratinocyte derived interferon](#)

- 7393846- [Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders](#)
- 7393934- [Human G-protein chemokine receptor \(CCR5\) HDGNR10](#)
- 7396663- [Isolated polynucleotide encoding a G-protein coupled receptor](#)
- 7402312- [Antibodies to vascular endothelial growth factor 2 \(VEGF-2\)](#)
- 7410659- [Methods for the treatment of peripheral neural and vascular ailments](#)
- 7411051- [Antibodies to HDPPA04 polypeptide](#)
- 7411054- [25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor](#)
- 7413728- [Immune modulator](#)
- 7417033- [Antisense oligonucleotides capable of inhibiting the formation of capillary tubes by endothelial cells](#)
- 7456256- [BGS 4](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

